Real-world clinical validation study: individualized warfarin dosing strategy integrating genetic polymorphisms and Bayesian
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-08 · 399 (11) · 17061-17070
DOI: 10.1007/s00210-026-05447-x ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 16.05.2026. Verfasst von Pu Bai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ordos Central Hospital, No. 6 Sudu Street, Kangbashi District, Ordos, 017010, China. Hauptthemen laut MEDLINE: Warfarin, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
This study aims to evaluate the clinical efficacy and safety of Bayesian pharmacogenomic-guided dosing. In this study, sixty patients enrolled from January 2022 to December 2023 were assigned to either a Bayesian pharmacogenomic-guided dosing group (n = 30) or a conventional dosing group (n = 30). The Bayesian pharmacogenomic-guided dosing group received warfarin maintenance doses optimized by clinical pharmacists using a pharmacokinetic-pharmacodynamic model that incorporated demographic, clinical, and genetic variables. Patients in the conventional dosing group received warfarin dose adjustments based on clinical judgment and international normalized ratio (INR). During a 3-month follow-up, both groups were monitored for the following parameters: daily warfarin dose (mg/day), INR, time to first therapeutic INR, time to stable anticoagulation, percentage of time in target range, and safety outcomes. The Bayesian pharmacogenomic-guided dosing group outperformed the conventional group across all efficacy endpoints. The Bayesian pharmacogenomic-guided dosing group achieved a significantly shorter time to first therapeutic INR than the conventional group (7.71 ± 3.95 days vs. 19.18 ± 9.08 days, P < 0.01). The rates of achieving stable anticoagulation were significantly higher in the Bayesian pharmacogenomic-guided dosing group than in the conventional group (within 2 weeks: 50.0% vs. 10.0%, P < 0.01; within 3 weeks: 90.0% vs. 33.3%, P < 0.01). Compared to the conventional group, the percentage of time in target range was significantly higher in the Bayesian pharmacogenomic-guided dosing group over 30 days (86.8% vs. 16.77%, P < 0.001). Safety analysis showed that the incidence of adverse events was significantly lower in the Bayesian pharmacogenomic-guided dosing group (3.33% vs. 40.0%, P < 0.01). No major bleeding events occurred in either group. Relative to empirical management, Bayesian pharmacogenomic-guided dosing not only enhanced anticoagulation precision but also accelerated the achievement of therapeutic targets. These findings support the implementation of model-informed precision dosing strategies in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Ordos Central Hospital, No. 6 Sudu Street, Kangbashi District, Ordos, 017010, China.
- Department of Pharmacy, Ordos Central Hospital, No. 6 Sudu Street, Kangbashi District, Ordos, 017010, China. shiban26@sina.com.
- Department of Pharmacy, Ordos Central Hospital, No. 6 Sudu Street, Kangbashi District, Ordos, 017010, China. xiepeitao57@163.com.
- Department of Pharmacy, Ordos Central Hospital, No. 6 Sudu Street, Kangbashi District, Ordos, 017010, China. lls8590623@163.com.
Zitieren
APA
Bai, P., Shi, C., Xie, P., & Lu, L. (2026). Real-world clinical validation study: individualized warfarin dosing strategy integrating genetic polymorphisms and Bayesian. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(11), 17061-17070. https://doi.org/10.1007/s00210-026-05447-x
Vancouver
Bai P, Shi C, Xie P, Lu L. Real-world clinical validation study: individualized warfarin dosing strategy integrating genetic polymorphisms and Bayesian. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(11):17061-17070. doi:10.1007/s00210-026-05447-x
BibTeX
@article{Bai2026,
author = {Bai, Pu and Shi, Cunfa and Xie, Peitao and Lu, Lishan},
title = {Real-world clinical validation study: individualized warfarin dosing strategy integrating genetic polymorphisms and Bayesian},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {11},
pages = {17061--17070},
doi = {10.1007/s00210-026-05447-x}
}
EUVIMED